Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Michael Hayden joins Med BioGene's board

This article was originally published in Clinica

Executive Summary

Canadian molecular diagnostics specialist Med BioGene has appointed Michael Hayden to its board of directors. Dr Hayden is a professor of medical genetics at the University of British Columbia, Vancouver, Canada, and director of a genetic research facility there, the Center for Molecular Medicine and Therapeutics. He has also served as the scientific director of the Canadian Genetic Diseases Network since it was founded in 1990, and is director and chief scientific officer of Xenon Pharmaceuticals, a privately-held biotech company. Vancouver-based Med BioGene's lead product is LungExpress Dx, a test to help improve staging for non-small cell lung cancer patients, identifying patients with a higher risk of mortality. The firm hopes to launch it in the US this year.

Advertisement
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT045263

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel